All In Biotech

Drug Trial Radar · NCT06096259

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

512

Planned (sponsor's estimate)

Start

May 6, 2024

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arthritis Foundation
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.

Conditions

  • Osteoarthritis, Knee
  • Post-traumatic Osteoarthritis
  • ACL Tear

Interventions

  • MetforminDrug

    Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.

  • PlaceboDrug

    The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. KOOS Pain ScoreTime frame: Average of 12 and 24 months
  2. Modified MOAKS Cartilage ScoreTime frame: 24 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Hospital for Special Surgery

    New York, New York · Recruiting

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.